GSM gold starGSM Global
中文版 · Chinese

FDA Approves MYQORZO Label Update on November 16: Phase 3 MAPLE-HCM Data Added, With the Week 24 Peak Oxygen Uptake Endpoint Met and Five of Six Secondary Endpoints Significantly Improved

Monday, November 16, 2026 · Health · GSM News

Cytokinetics announced on November 16 that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application adding data from the Phase 3 MAPLE-HCM trial to the U.S. Prescribing Information for MYQORZO (aficamten). MYQORZO is a cardiac myosin inhibitor approved to treat adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), to improve functional capacity and symptoms.

MAPLE-HCM was a Phase 3, multi-center, randomized, double-blind, double-dummy controlled trial enrolling 175 adults, comparing MYQORZO with the standard-of-care beta-blocker metoprolol, each as monotherapy, on peak oxygen uptake (pVO2). The trial met its primary endpoint of change in pVO2 from baseline to Week 24, with an effect consistent across all prespecified subgroups.

Five of six secondary endpoints improved significantly, including New York Heart Association Functional Class, the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score, NT-proBNP, post-Valsalva left ventricular outflow tract gradient and left atrial volume index. Overall adverse event rates were similar between groups; the label data show hypertension in 15% of patients on MYQORZO versus 3% on metoprolol in MAPLE-HCM.

MYQORZO was first approved by the FDA in December 2025. Its U.S. label carries a Boxed Warning for the risk of heart failure, and echocardiogram monitoring is required under a Risk Evaluation and Mitigation Strategy (REMS) program. The update adds no new indication; it places the head-to-head evidence against metoprolol into the label.

Published by GSM · USA (original Chinese edition)

Photo: Wikimedia Commons, File:Blausen 0166 Cardiomyopathy Hypertrophic.png — Author: BruceBlaus / Blausen.com staff. Licensing: CC BY 3.0.

Latest in Health